Dabur India Ltd. shares experienced a 2% drop on Monday, reaching a low of Rs 377.05. The decline followed an administrative warning issued by the Securities and Exchange Board of India (SEBI) concerning the company's delay in disclosing a warning letter received from the US Food and Drug Administration (USFDA) in July 2026.
SEBI Cites Regulation Breach
SEBI's warning, communicated to Dabur on November 6, 2026, explicitly stated that the company failed to disclose the USFDA communication within the prescribed timeline. This delay constitutes a violation of Regulation 30(6)(iii) of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.
The market regulator expressed serious concern over the lapse, advising Dabur and its board of directors to ensure such delays do not recur. SEBI also cautioned that any future repetition of the violation could lead to enforcement action under the SE SEBI Act, 1992, and other applicable rules and regulations.
Dabur's Response and Directives
In its November 6 exchange filing, Dabur acknowledged the warning and clarified that the administrative communication itself has no financial or operational impact on the company. Dabur stated it would take all necessary steps to address the concerns and directions outlined in SEBI's letter, reiterating its consistent adherence to SEBI's listing requirements.
SEBI has directed Dabur to present the administrative warning letter to its board of directors at their upcoming meeting. Furthermore, the company must forward the board's comments on the corrective measures taken to ensure future compliance. Separately, Dabur was instructed to disclose the administrative warning to the stock exchanges under Regulation 30.
Market Reaction
The news led to an immediate reaction in the market, with Dabur India shares opening at Rs 380.60 before touching their session low. Investors are closely watching how Dabur implements SEBI's directives and whether further details regarding the USFDA letter emerge.